Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Zacks
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2025, Organon (OGN) reported revenue of $1.51 billion, down 5.3% over the same period last year. EPS came in at $0.63, compared to $0.90 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.52 billion, representing a surprise of -1.08%. The company delivered an EPS surprise of -13.46%, with the consensus EPS estimate being $0.73.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Established Brands- U.S.- Respiratory- Other: $11 million compared to the $11.41 million average estimate based on three analysts. The reported number represents a change of -15.4% year over year. Revenue- Established Brands- U.S.- Non-Opioid Pain, Bone and Dermatology- Vtama: $31 million versus the three-analyst average estimate of $33.23 million. Revenue- Women's Health- Int'l- NuvaRing: $18 million versus the three-analyst average estimate of $16.74 million. The reported number represents a year-over-year change of 0%. Revenue- Women's Health- U.S.- NuvaRing: $-2 million versus $6.69 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -133.3% change. Revenue- Women's Health- Nexplanon/Implanon NXT: $211 million versus $228.79 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -18.2% change. Revenue- Women's Health- Follistim AQ: $58 million compared to the $67.92 million average estimate based on three analysts. The reported number represents a change of -10.8% year over year. Revenue- Established Brands Total: $913 million versus $878.99 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.4% change. Revenue- Biosimilars Total: $181 million compared to the $182.09 million average estimate based on three analysts. The reported number represents a change of +11% year over year. Revenue- Women?s Health Total: $398 million compared to the $442.38 million average estimate based on three analysts. The reported number represents a change of -14.6% year over year. Revenue- Other Total: $15 million compared to the $20.97 million average estimate based on three analysts. The reported number represents a change of -46.4% year over year. Revenue- Women's Health- NuvaRing: $15 million versus $23.43 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -37.5% change. Revenue- Biosimilars- Renflexis: $61 million compared to the $60.06 million average estimate based on three analysts. The reported number represents a change of -6.2% year over year.

View all Key Company Metrics for Organon here>>>

Shares of Organon have returned -10.7% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include

Stock #1: A Disruptive Force with Notable Growth and Resilience

Stock #2: Bullish Signs Signaling to Buy the Dip

Stock #3: One of the Most Compelling Investments in the Market

Stock #4: Leader In a Red-Hot Industry Poised for Growth

Stock #5: Modern Omni-Channel Platform Coiled to Spring

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.

See Our Newest 5 Stocks Set to Double Picks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Organon & Co. (OGN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Outras notícias